Significance of erb-B2 immunoreactivity in cervical cancer

Daniela Califano, Simona Losito, Carmela Pisano, Giovanni Santelli, Stefano Greggi, Francesco Iodice, Giovanni DiVagno, Giustino Silvestro, Rosa Tambaro, Roberta Formato, Vincenzo Rosario Iaffaioli, Massimo Di Maio, Sandro Pignata

Research output: Contribution to journalArticlepeer-review


C-erbB2 is over-expressed or amplified in many carcinomas. We assessed the relationship between erb-B2 immunoreactivity, and its predictive role in progression-free survival and treatment outcome in patients with cervical carcinoma. Sections from 65 cervical carcinoma were immunostained with antiboty to p185 erbB2. Immunoreactive ErbB2 was found in 25 patients (38%) [+ 15 pts. (23%); ++ 10 pts. (15%)]. There were no correlation with age, performance status, grading and histology. Erb-B2 immunoreactivity significantly correlated with stage of the disease. Positive immunoreacivity was found in 63%, 44%, 14% and 0% of stage I, II, III and IV carcinomas, (p = 0.0045). Progression-free survival was longer in erb-B2 positive patients without reaching significance. No correlation was found between erbB2 and response to radiotherapy or chemotherapy. In conclusion, a significant proportion of stage I and II cervical cancer express erb-B2 compared to more advanced stages. Expression of the oncogene does not appear to be related to prognosis or treatment outcome.

Original languageEnglish
Pages (from-to)2071-2076
Number of pages6
JournalFrontiers in Bioscience
Issue numberSUPPL. 1
Publication statusPublished - 2006


  • Adenocarcinoma
  • Cancer
  • Cervical Cancer
  • Cervix
  • erb-b2
  • Neoplasia
  • Squamous Cell Carcinoma
  • Tumor

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Cell Biology


Dive into the research topics of 'Significance of erb-B2 immunoreactivity in cervical cancer'. Together they form a unique fingerprint.

Cite this